Vyome Biosciences, a dermatology company, has closed Series B financing of $8 million led by Sabre Partners, along with existing Series A investors Kalaari Capital and Aarin Capital.
Vyome is pioneering the development of a deep pipeline of molecules, including ‘first in class’ Molecular Replacement Therapeutics (MRT) for killing dandruff-causing fungus, new antibiotics using Dual Action Rational Therapeutics (DART) technology that kill resistant acne-causing bacteria. Vyome recently successfully completed clinical studies on VB001 and VB2421 for mild to moderate dandruff.
Speaking on the occasion, N Venkat, Co-Founder and CEO of Vyome said, “This financing is a major landmark in Vyome’s journey to translate cutting edge science into differentiated products and innovative commercialisation strategies, and gives the company substantial firepower to drive the completion of critical milestones of USFDA filings as well as Phase 1 and Phase 2 clinical research for some of its lead compounds and other development and commercialisation efforts of its Rx and OTC pipeline.”
Sabre Partners has invested over $300 million in India. Sabre also has an infrastructure fund and a healthcare focused venture capital fund called ‘Spring Healthcare’, through which this investment in Vyome was made and through which Sabre has built a healthcare and life sciences portfolio over the past four years.
“We are delighted to partner with a world-class team that is applying science and critical understanding of unmet needs to develop unique platform technologies and products for the $20 billion global dermatology market” said Maliwal, Founder and Managing Partner, Sabre Partners.
EH News Bureau
- Advertisement -
